Press Room


    Press Release - February 15, 2001

    Eldon Smith MD Appointed to Pheromone Sciences Board of Directors

    Toronto, Ontario (February 15, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Eldon R. Smith, MD, FRCP(C), FACC, to its Board of Directors.

    Dr. Eldon Smith brings a wealth of knowledge in medical research and extensive healthcare experience to Pheromone Sciences Board of Directors. He is presently Professor at the University of Calgary Medical School, where he was formerly the Dean of the Faculty of Medicine, and previously head of the Department of Medicine and head of the Division of Cardiology. Dr. Smith is a leading clinician and research scientist who has made major contributions to the Canadian cardiology and medical communities. He has served as President of the Canadian Cardiovascular Society, Chairman of the Scientific Grant Review Committee of the Heart and Stroke Foundation, and President of the Association of Canadian Medical Colleges. He is currently a Trustee of the Alberta Heritage Foundation for Medical Research and a member of the Premier's Advisory Council on Health for the Province of Alberta. He is also President of the Peter Lougheed Medical Research Foundation.

    In addition to his medical practice, Dr Smith serves on the Board of Directors of a number of public companies including Canadian Natural Resources Ltd, Vasogen Inc. and BioMax Technologies Inc. He also serves on the Advisory Boards of the Canadian Medical Discovery Fund and a number of Biotechnology and Pharmaceutical Companies.

    "Dr. Smith is a powerful addition to the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Eldon brings a rare combination of clinical, medical and business experience. Eldon has been used extensively by several of Canada's top funds to evaluate and mentor companies from inception to commercialization."

    The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Charles Borg PhD. Mr. Borg remains a member of senior management retaining the position Executive Vice- President and Chief Operating Officer.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News